Three-Dimensional Printing of Medicinal Products and the Challenge of Personalized Therapy

By 3-dimensional (3D) printing, solid objects of any shape are fabricated through layer-by-layer addition of materials based on a digital model. At present, such a technique is broadly exploited in many industrial fields because of major advantages in terms of reduced times and costs of development...

Full description

Saved in:
Bibliographic Details
Published inJournal of pharmaceutical sciences Vol. 106; no. 7; pp. 1697 - 1705
Main Authors Zema, Lucia, Melocchi, Alice, Maroni, Alessandra, Gazzaniga, Andrea
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.07.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:By 3-dimensional (3D) printing, solid objects of any shape are fabricated through layer-by-layer addition of materials based on a digital model. At present, such a technique is broadly exploited in many industrial fields because of major advantages in terms of reduced times and costs of development and production. In the biomedical and pharmaceutical domains, the interest in 3D printing is growing in step with the needs of personalized medicine. Printed scaffolds and prostheses have partly replaced medical devices produced by more established techniques, and more recently, 3D printing has been proposed for the manufacturing of drug products. Notably, the availability of patient-tailored pharmaceuticals would be of utmost importance for children, elderly subjects, poor and high metabolizers, and individuals undergoing multiple drug treatments. 3D printing encompasses a range of differing techniques, each involving advantages and open issues. Particularly, solidification of powder, extrusion, and stereolithography have been applied to the manufacturing of drug products. The main challenge to their exploitation for personalized pharmacologic therapy is likely to be related to the regulatory issues involved and to implementation of production models that may allow to efficiently turn the therapeutic needs of individual patients into small batches of appropriate drug products meeting preset quality requirements.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-3549
1520-6017
1520-6017
DOI:10.1016/j.xphs.2017.03.021